MA27318A1 - Comprime de lasofoxifene et son enrobage - Google Patents
Comprime de lasofoxifene et son enrobageInfo
- Publication number
- MA27318A1 MA27318A1 MA28036A MA28036A MA27318A1 MA 27318 A1 MA27318 A1 MA 27318A1 MA 28036 A MA28036 A MA 28036A MA 28036 A MA28036 A MA 28036A MA 27318 A1 MA27318 A1 MA 27318A1
- Authority
- MA
- Morocco
- Prior art keywords
- lasofoxifene
- coating
- active ingredient
- tablet
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 10 Juillet 2002 60/395,090 Comprimé de lasofoxifène et son enrobage Des compositions pharmaceutiques ayant une distribution et activité uniformes de médicament, utilisant du lasofoxifène comme ingrédient actif et contenant un dioxyde de silicium pour réduire la perte d'ingrédient actif au cours du procédé de production, ainsi que des procédés pour la production de ces compositions sont décrits. La triacétine d'enrobage, servant de plastifiant, se révèle conférer une bonne stabilité au lasofoxifène.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39509002P | 2002-07-10 | 2002-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27318A1 true MA27318A1 (fr) | 2005-05-02 |
Family
ID=30115812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28036A MA27318A1 (fr) | 2002-07-10 | 2005-01-10 | Comprime de lasofoxifene et son enrobage |
Country Status (36)
Country | Link |
---|---|
US (2) | US20040057992A1 (fr) |
EP (1) | EP1534248B1 (fr) |
JP (2) | JP4446446B2 (fr) |
KR (1) | KR100782693B1 (fr) |
CN (1) | CN100344278C (fr) |
AP (1) | AP2005003201A0 (fr) |
AR (1) | AR040434A1 (fr) |
AT (1) | ATE550017T1 (fr) |
AU (1) | AU2003247017B2 (fr) |
BR (1) | BR0312563A (fr) |
CA (1) | CA2489407C (fr) |
CY (1) | CY1112892T1 (fr) |
DK (1) | DK1534248T3 (fr) |
EA (1) | EA007268B1 (fr) |
EC (1) | ECSP055528A (fr) |
ES (1) | ES2395123T3 (fr) |
HK (1) | HK1077747A1 (fr) |
HN (1) | HN2003000206A (fr) |
HR (1) | HRP20041196A2 (fr) |
IL (2) | IL165746A0 (fr) |
IS (1) | IS7594A (fr) |
MA (1) | MA27318A1 (fr) |
MX (1) | MXPA05000394A (fr) |
NO (1) | NO20050018L (fr) |
NZ (1) | NZ537278A (fr) |
OA (1) | OA12883A (fr) |
PA (1) | PA8576201A1 (fr) |
PE (1) | PE20040104A1 (fr) |
PL (1) | PL374913A1 (fr) |
PT (1) | PT1534248E (fr) |
SI (1) | SI1534248T1 (fr) |
TN (1) | TNSN05006A1 (fr) |
TW (1) | TW200406222A (fr) |
UY (1) | UY27886A1 (fr) |
WO (1) | WO2004006895A1 (fr) |
ZA (1) | ZA200410196B (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
EP1871359A1 (fr) * | 2005-04-07 | 2008-01-02 | Miso Sabovic | Retardement du processus de vieillissement et des troubles provoques par le vieillissement |
WO2006118137A1 (fr) * | 2005-04-26 | 2006-11-09 | Dainippon Sumitomo Pharma Co., Ltd. | Préparation granulaire contenant un dérivé de biguanide |
GB0516604D0 (en) * | 2005-08-12 | 2005-09-21 | Sandoz Ag | Rapidly dispersing/disintegrating compositions |
EP3173084B1 (fr) | 2005-11-11 | 2019-10-23 | Boehringer Ingelheim International GmbH | Dérivés de quinazoline pour le traitement de cancers |
LT2487166T (lt) | 2007-02-23 | 2016-11-10 | Gilead Sciences, Inc. | Terapinių agentų farmakokinetinių savybių moduliatoriai |
CA2835910C (fr) * | 2007-04-25 | 2016-06-28 | Warner Chilcott Company, Llc | Uniformite amelioree de contenu de vitamine d dans des formes dosifiees pharmaceutiques |
US20100055180A1 (en) * | 2007-10-10 | 2010-03-04 | Mallinckrodt Baker, Inc. | Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof |
CN101820863A (zh) * | 2007-10-10 | 2010-09-01 | 马林克罗特贝克公司 | 直接可压制的高功能性颗粒状微晶纤维素基赋形剂、其制备方法和用途 |
WO2009135067A1 (fr) * | 2008-05-01 | 2009-11-05 | Wyeth | Formulations de vernis pharmaceutique |
SG190618A1 (en) * | 2008-05-02 | 2013-06-28 | Gilead Sciences Inc | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
US9545381B2 (en) * | 2009-07-06 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
RU2661402C2 (ru) * | 2011-10-17 | 2018-07-16 | Лексикон Фармасьютикалз, Инк. | Твердые дозированные формы (s)-этил 2-амино-3-(4-(2-амино-6((r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата |
DK2851075T3 (da) | 2012-05-14 | 2022-01-31 | Shionogi & Co | Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat |
PL3043778T3 (pl) * | 2013-09-13 | 2018-04-30 | Bayer Pharma Aktiengesellschaft | Kompozycje farmaceutyczne zawierające refametinib |
RU2539375C1 (ru) * | 2013-11-07 | 2015-01-20 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция в форме таблетки и способ ее получения |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
CN103830196A (zh) * | 2014-03-14 | 2014-06-04 | 王志刚 | 一种酒石酸拉索昔芬分散片及其制备方法 |
TWI535784B (zh) | 2014-08-26 | 2016-06-01 | 財團法人工業技術研究院 | 剪切增稠配方、及包含其之複合材料 |
CN105434444B (zh) * | 2014-09-29 | 2021-02-05 | 上海奥奇医药科技有限公司 | 一种A-失碳-5α雄甾烷化合物的口服制剂 |
US20190183850A1 (en) * | 2016-07-25 | 2019-06-20 | Canopy Growth Corporation | New cannabis tablet formulations and compositions and methods of making the same |
JP6892151B2 (ja) | 2016-10-11 | 2021-06-23 | デューク ユニバーシティ | Er+乳がんのラソフォキシフェン処置 |
EP3773524A4 (fr) | 2018-04-10 | 2021-12-22 | Duke University | Traitement du cancer du sein avec du lasofoxifène |
GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
CN114288258A (zh) * | 2022-02-18 | 2022-04-08 | 山东新时代药业有限公司 | 一种单硝酸异山梨酯片及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4182A (en) * | 1845-09-09 | Island | ||
US4880636A (en) * | 1988-05-13 | 1989-11-14 | Franz Robert M | Film coated tablet of ranitidine HCl |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
US6372457B1 (en) | 1997-01-14 | 2002-04-16 | Arkion Life Sciences Llc | Process and materials for production of glucosamine |
KR200161927Y1 (ko) * | 1997-08-26 | 1999-12-01 | 윤종용 | 냉장고 |
YU26700A (sh) * | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
US6436977B1 (en) * | 1999-09-29 | 2002-08-20 | Pfizer Inc. | Dosing regimens for lasofoxifene |
US6419956B1 (en) * | 1999-12-30 | 2002-07-16 | Ancile Pharmaceuticals | Odor-masking coating for a pharmaceutical preparation |
EP1145719A3 (fr) * | 2000-03-10 | 2001-11-14 | Pfizer Products Inc. | Utilisation d'un sel ferreux pour l'inhibition de la dégradation oxydative de compositions pharmaceutiques |
AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
OA12596A (en) * | 2001-05-01 | 2006-06-08 | Pfizer Prod Inc | Method for manufacturing a low dose pharmaceuticalcomposition. |
PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
-
2003
- 2003-06-23 PA PA20038576201A patent/PA8576201A1/es unknown
- 2003-06-30 KR KR1020057000369A patent/KR100782693B1/ko active IP Right Grant
- 2003-06-30 PT PT03764059T patent/PT1534248E/pt unknown
- 2003-06-30 AT AT03764059T patent/ATE550017T1/de active
- 2003-06-30 BR BR0312563-7A patent/BR0312563A/pt not_active IP Right Cessation
- 2003-06-30 MX MXPA05000394A patent/MXPA05000394A/es active IP Right Grant
- 2003-06-30 EP EP03764059A patent/EP1534248B1/fr not_active Expired - Lifetime
- 2003-06-30 PL PL03374913A patent/PL374913A1/xx not_active Application Discontinuation
- 2003-06-30 WO PCT/IB2003/003074 patent/WO2004006895A1/fr not_active Application Discontinuation
- 2003-06-30 OA OA1200500007A patent/OA12883A/en unknown
- 2003-06-30 IL IL16574603A patent/IL165746A0/xx unknown
- 2003-06-30 JP JP2004521001A patent/JP4446446B2/ja not_active Expired - Fee Related
- 2003-06-30 NZ NZ537278A patent/NZ537278A/en unknown
- 2003-06-30 DK DK03764059.6T patent/DK1534248T3/da active
- 2003-06-30 EA EA200401583A patent/EA007268B1/ru not_active IP Right Cessation
- 2003-06-30 ES ES03764059T patent/ES2395123T3/es not_active Expired - Lifetime
- 2003-06-30 CA CA002489407A patent/CA2489407C/fr not_active Expired - Fee Related
- 2003-06-30 AP AP2005003201A patent/AP2005003201A0/xx unknown
- 2003-06-30 SI SI200332150T patent/SI1534248T1/sl unknown
- 2003-06-30 AU AU2003247017A patent/AU2003247017B2/en not_active Ceased
- 2003-06-30 CN CNB038162881A patent/CN100344278C/zh not_active Expired - Fee Related
- 2003-07-01 US US10/612,679 patent/US20040057992A1/en not_active Abandoned
- 2003-07-04 TW TW092118389A patent/TW200406222A/zh unknown
- 2003-07-07 PE PE2003000682A patent/PE20040104A1/es not_active Application Discontinuation
- 2003-07-07 HN HN2003000206A patent/HN2003000206A/es unknown
- 2003-07-08 UY UY27886A patent/UY27886A1/es not_active Application Discontinuation
- 2003-07-08 AR AR20030102454A patent/AR040434A1/es not_active Application Discontinuation
-
2004
- 2004-12-13 IS IS7594A patent/IS7594A/is unknown
- 2004-12-13 IL IL165746A patent/IL165746A/en active IP Right Grant
- 2004-12-17 HR HR20041196A patent/HRP20041196A2/hr not_active Application Discontinuation
- 2004-12-17 ZA ZA200410196A patent/ZA200410196B/en unknown
-
2005
- 2005-01-03 NO NO20050018A patent/NO20050018L/no not_active Application Discontinuation
- 2005-01-10 EC EC2005005528A patent/ECSP055528A/es unknown
- 2005-01-10 MA MA28036A patent/MA27318A1/fr unknown
- 2005-01-10 TN TNP2005000006A patent/TNSN05006A1/fr unknown
- 2005-11-04 HK HK05109850A patent/HK1077747A1/xx not_active IP Right Cessation
-
2006
- 2006-11-09 JP JP2006303440A patent/JP2007031451A/ja active Pending
- 2006-12-22 US US11/615,511 patent/US7553500B2/en not_active Expired - Fee Related
-
2012
- 2012-06-06 CY CY20121100504T patent/CY1112892T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27318A1 (fr) | Comprime de lasofoxifene et son enrobage | |
MA27017A1 (fr) | Procede pour la production d'une composition pharmaceutique a faible dose ayant une distribution et activite medicamenteuses uniformes | |
UA84726C2 (ru) | Производные простагландинов, способ их получения, фармацевтическая композиция (варианты) и способ лечения глаукомы или гипертензии глаза | |
NO20062051L (no) | Farmasoytisk virkestoffinneholdende formulering med belegg | |
CR20240093A (es) | Inhibidores de NLRP3 | |
MY137348A (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
MA25809A1 (fr) | Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase | |
WO2004108162A3 (fr) | Composition pharmaceutique et methode de traitement | |
WO2004055006A8 (fr) | Nouveaux composes presentant un effet inhibiteur selectif de la gsk3 | |
WO2003082853A8 (fr) | Nouveaux composes | |
EP1283054A4 (fr) | Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments | |
MA27867A1 (fr) | Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif. | |
CA2214026A1 (fr) | Compositions pharmaceutiques comprenant des inhibiteurs de la monoamine oxydase b | |
DK1383540T3 (da) | Fremgangsmdåer og farmaceutiske sammensætninger til sårheling | |
WO2006053089A3 (fr) | Methodes et formulations permettant de preparer des compositions pharmaceutiques contenant du bupropion | |
TW200640465A (en) | New pharmaceutically active compounds for the treatment of respiratory diseases | |
SE0102440D0 (sv) | New compound | |
HK1098352A1 (en) | Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis | |
HK1079688A1 (en) | Statin product for enhancing cognitive maintenance | |
HUP0203338A2 (hu) | Integrin receptor ligandumok | |
TW200517127A (en) | Novel composition | |
HUP0300191A2 (hu) | 2,6-Diamino-6-metil-heptánsav és származékai, eljárás ezek előállítására és alkalmazásuk | |
UA86767C2 (ru) | АЗАИНДОЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ ФАКТОРА Ха | |
BG108151A (en) | Caloporoside derivatives, methods for the production thereof and their use | |
GR1010670B (el) | Φαρμακευτικη συνθεση που περιεχει απιξαβανη και μεθοδος παρασκευης αυτης |